InvestorsHub Logo
Post# of 4963948
Next 10
Followers 37
Posts 4190
Boards Moderated 0
Alias Born 10/18/2016

Re: None

Wednesday, 02/21/2018 9:31:54 AM

Wednesday, February 21, 2018 9:31:54 AM

Post# of 4963948
Compensated Awareness Post View Disclaimer
Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Issues Corporate Update Detailing Q1 2018 Milestones

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of the University of British Columbia, its subsidiary’s progress toward the commencement of human trials in Puerto Rico studying lead cannabis strain CTL-X for pain management, its reception of a Health Canada dealer license through subsidiary Cannevert Therapeutics Ltd. (“CTL”) and CTL’s initiation of a cancer research project aimed at assessing the effects of several human cancer cell lines against cannabis strains, among others.

To view the full press release, visit http://nnw.fm/CjoU5

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.